Cfdna Methylation Profiling Distinguishes Lineage-Specific Hematologic Malignancies

Introduction: Hematologic (heme) malignancies and their precursor conditions are highly prevalent. They are also diverse in biology, clinical presentation, and outcomes, underlining the importance of differentiating them. Previously, we demonstrated that a blood-based targeted methylation assay detected multiple cancer types across stages. Here, we examined test performance on various heme cancers, identifying specific methylation signatures. Methods: From the second substudy (training set) of the Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978), we evaluated 325 participants from 17 different heme disease subtypes and 3,211 non-cancer controls enrolled without a cancer diagnosis. A cross-validated mutual information-based algorithm was used to identify features that discriminated heme subtypes. The resulting feature distribution was visualized using uniform manifold approximation and projection (UMAP) dimensionality reduction on held-out data. In cross validation with feature selection, we then trained a multinomial classifier to distinguish from among the major heme cancers and non-cancer and correlated the model9s class probabilities to positions in feature space. Results: Dimensionality reduction and visualization of input features demonstrated that heme malignancies separated into five major clusters reflecting developmental lineages and disease ontogeny: myeloid, circulating lymphomas, hodgkin lymphomas, non-hodgkin lymphomas, and plasma cell neoplasm. The position of samples within each heme cluster correlated with the cancer signal strength. At 99.4% specificity [95% CI: 99.1, 99.7], heme cancer detection was 74.5% [69.4, 79.1] overall, 67.7% [41.1, 87.8] for myeloid, 77.9% [66.3, 86.9] for circulating lymphomas, 90.7% [73.2, 98.4] for hodgkin lymphomas, 68.6% [60.4, 76.1] for other non-hodgkin lymphomas, and 78.8% [67.0, 87.9] for plasma cell neoplasms. Of 18 non-cancer participants who were classified as having heme cancers, 4 were predicted as myeloid, 6 as circulating lymphoid, and 8 as other non-hodgkin lymphoid neoplasms ( Conclusion: Methylation features of cfDNA in patients with heme malignancies delineated five major clusters that reflected disease ontogeny and heme lineage. Lineage-specific signals followed a gradient suggestive of variation in disease-related methylation or tumor DNA shedding. These findings contribute to the understanding of biological signals that arise from various heme conditions. Since in general, most cfDNA arises from blood lineages, this knowledge will guide further efforts towards removing interfering biological signals from cfDNA-based cancer detection assays and achieving even more sensitive detection of multiple cancer types. Citation Format: Qinwen Liu, Rita Shaknovich, Xiaoji Chen, Zhao Dong, M. C. Maher, Samuel Gross, Alexander P. Fields, Jan Schellenberger, Kathryn N. Kurtzman, Eric T. Fung, Anne-Renee Hartman, Earl Hubbell, Arash Jamshidi, Alexander M. Aravanis, Oliver Venn. cfDNA methylation profiling distinguishes lineage-specific hematologic malignancies [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 139.